Solid Biosciences Inc. SLDB
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2018 · data as of November 13, 2026
Solid Biosciences Inc. (SLDB) is a healthcare company listed in the US with a market value of about $763M.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -57%.
About Solid Biosciences
Solid Biosciences is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2018. It was profitable in 0 of the last 10 years in our data. Its share count rose by 928% over three years (dilution for shareholders).
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $8M | $14M | $0 | $0 | $0 | $0 | $0 |
| Net income | -$174M | -$125M | -$96M | -$86M | -$72M | -$88M | -$117M | -$75M | -$52M | -$22M |
| Free cash flow | -$157M | -$101M | -$96M | -$101M | -$79M | -$57M | -$97M | -$78M | -$46M | -$21M |
| EPS (diluted) | $-1.99 | $-3.06 | $-4.83 | $-10.10 | $-10.14 | $-25.50 | $-2.91 | $-2.25 | $-2.88 | $-10.14 |
| Net margin | — | — | — | -1062.3% | -530.0% | — | — | — | — | — |
| ROIC | -89.1% | -81.0% | -54.5% | -35.4% | -27.2% | -51.2% | -109.3% | -45.6% | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 14 analysts is $18.71, 174% above the current price; targets range from $11.00 to $26.00; the consensus rating is “Strong buy”; expected EPS is $-1.61 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Solid Biosciences pay a dividend?
Not currently.
Is Solid Biosciences a good stock to buy?
We do not give buy or sell advice. Solid Biosciences scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.